Document is current
Any future updates will be listed below
-
Authors
Chardon, Florence M. https://orcid.org/0000-0001-8858-989X
McDiarmid, Troy A.
Page, Nicholas F.
Daza, Riza M. https://orcid.org/0000-0003-1635-8675
Martin, Beth K.
Domcke, Silvia
Regalado, Samuel G.
Lalanne, Jean-Benoît
Calderon, Diego https://orcid.org/0000-0002-6990-9066
Li, Xiaoyi
Starita, Lea M. https://orcid.org/0000-0003-2870-5099
Sanders, Stephan J.
Ahituv, Nadav https://orcid.org/0000-0002-7434-8144
Shendure, Jay https://orcid.org/0000-0002-1516-1865
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG011966)
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 10 September 2024
First Online: 18 September 2024
Competing interests
: S.J.S. receives research funding from BioMarin Pharmaceutical Incorporated. N.A. is the cofounder and on the scientific advisory board of Regel Therapeutics and receives funding from BioMarin Pharmaceutical Incorporated. J.S. is a scientific advisory board member, consultant and/or co-founder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Prime Medicine, Somite Therapeutics and Pacific Biosciences. All other authors declare no competing interests.
